Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Fineline Cube Jun 30, 2026
Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Fineline Cube Jun 30, 2026
Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Fineline Cube Jun 30, 2026
Company Deals

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

Fineline Cube Jun 30, 2026
Company Deals

Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Fineline Cube Jun 30, 2026
Company Drug

AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s State Council Unveils Comprehensive Plan to Boost Beijing’s Healthcare Sector

Fineline Cube Dec 1, 2023

The State Council has unveiled a comprehensive “Work Plan” aimed at enhancing Beijing’s service industry...

Company Deals

Bayer Partners with CrossBay Medical to Enhance Hormonal IUS Delivery System

Fineline Cube Dec 1, 2023

Germany’s Bayer (ETR: BAYN) has announced a strategic partnership with women’s health innovator CrossBay Medical...

Company Deals

Johnson & Johnson Acquires Laminar for $400 Million to Enhance Heart Rhythm Solutions

Fineline Cube Dec 1, 2023

Johnson & Johnson (J&J; NYSE: JNJ) has finalized the acquisition of medical device manufacturer Laminar...

Company Drug

Yingli Pharma Enrolls First Patient in Phase I Study for KRAS Inhibitor YL-17231 at MD Anderson

Fineline Cube Dec 1, 2023

Yingli Pharma, a US-based biopharmaceutical company focused on developing therapies for both the Chinese and...

Company Deals

MSD to Migrate IT Systems to AWS, Aiming for Faster Drug Discovery and Clinical Trials

Fineline Cube Dec 1, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced plans to transition a significant portion...

Company Drug

Akeso’s AK111 Achieves Key Efficacy Milestones in Phase III Trial for Plaque Psoriasis

Fineline Cube Dec 1, 2023

Akeso Biopharma (HKG: 9926), based in China, has announced that its pivotal Phase III clinical...

Company Drug

Sichuan Kelun-Biotech to Present Promising Phase II Results for SKB264 in mTNBC at SABCS 2023

Fineline Cube Dec 1, 2023

Sichuan Kelun Pharmaceutical Co., Ltd’s (SHE: 002422) innovative drug development subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co.,...

Company Drug

TG ImmunoPharma Secures U.S. FDA IND Approval for Promising mAb TGI-5 Targeting Multiple Cancers

Fineline Cube Dec 1, 2023

TG ImmunoPharma Co., Ltd, based in China, has announced that it has received Investigational New...

Company Drug

Insilico Medicine Launches Clinical Study for First-in-Class PHD Inhibitor ISM5411 in IBD

Fineline Cube Dec 1, 2023

Insilico Medicine, a China-based biotech leveraging generative artificial intelligence (AI), has announced the initiation of...

Company Drug

Simcere Secures NMPA Approval for Edaravone Sublingual Tablets Targeting Post-Stroke Cognitive Impairment

Fineline Cube Dec 1, 2023

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has received clinical trial approval from the National...

Company Drug

Everest Medicines Reports Positive Phase III Results for Velsipity in Ulcerative Colitis

Fineline Cube Dec 1, 2023

Everest Medicines (HKG: 1952), based in China, has announced positive topline results from a multi-center...

Company Medical Device

Acotec Secures FDA IDE Approval for AcoArt Litos Paclitaxel-Coated Balloon Catheter

Fineline Cube Dec 1, 2023

Acotec Scientific Holdings Ltd (HKG: 6669), based in China, has received Investigational Device Exemption (IDE)...

Company Deals

Perpetual Medicines Launches with $8 Million Seed Round, Led by Chengwei Capital

Fineline Cube Dec 1, 2023

Perpetual Medicines, a biotech firm with operations in Shanghai and Boston, has officially launched, announcing...

Company R&D

Takeda Reinforces Takeda Spark Incubator Program with Expanded Partnerships in China

Fineline Cube Nov 30, 2023

Takeda (TYO: 4502) has reportedly renewed and expanded a series of partnerships to bolster its...

Company

Novocure Restructures and Prioritizes Pipeline Amid Anticipated NSCLC Approval

Fineline Cube Nov 30, 2023

Novocure (NASDAQ: NVCR), a Switzerland-based developer of Tumor Treating Fields (TTFields) cancer therapeutic technology that...

Company Drug

AbbVie’s Telisotuzumab-Vedotin Shows Promising Results in NSCLC Phase 2 Trial

Fineline Cube Nov 30, 2023

AbbVie (NYSE: ABBV) has unveiled data from a Phase 2 trial of its potential first-in-class...

Company Deals

Boehringer Ingelheim Partners with Phenomic AI to Target Stroma-Rich Cancers

Fineline Cube Nov 30, 2023

Boehringer Ingelheim (BI), a German pharmaceutical company, has entered into a partnership with Canada’s Phenomic...

Company Drug

Jiangsu Hengrui Receives NMPA Approval for Esophageal Cancer and Breast Cancer Clinical Trials

Fineline Cube Nov 30, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received approval from the National Medical Products...

Company Drug

Asieris Pharmaceuticals’ Hexvix for Bladder Cancer Accepted for Review by China’s NMPA

Fineline Cube Nov 30, 2023

Asieris Pharmaceuticals (SHA: 688176), a specialist in urogenital cancer based in China, has announced that...

Company Drug

Jiangxi Jemincare’s KRAS Inhibitor Earns Breakthrough Designation from China’s CDE for NSCLC

Fineline Cube Nov 30, 2023

The China Center for Drug Evaluation (CDE) website has indicated that Jiangxi Jemincare Group’s proprietary...

Posts pagination

1 … 458 459 460 … 688

Recent updates

  • METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company
  • Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China
  • Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline
  • Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications
  • Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.